neophyte32
Senior Member (Voting Rights)
I disagree here. We've seen huge improvements in patients who had been severe or very severe for years. Generally, there aren't many fluctuations in these cases. They're extremely rare.Noise as in natural fluctuation.
Are you referring to the only LDA study conducted by Bonilla, which has been widely criticized for the way it was carried out?I know, and that's why I'm not completely pessimistic, as for most other trials. I also know from experience that it can be a very activating drug.
But if you look at the data from this trial...we've seen drugs that failed in controlled trials but looked more promising than that in their open-label trials.
Bonilla's 2021 study was retrospective, with no randomization, placebo group, or double-blinding. Doses ranged from 0.2 to 2 mg/day, with no proper investigation of the optimal dose. Finally, follow-up periods varied considerably (from less than one month to 17 months), with no rigorous assessment of a potential loss of effectiveness over time.
We've had five studies on LDN and just one poorly conducted study on LDA, even though LDA is the only treatment for which so many patients have reported almost miraculous improvements, particularly among severe and very severe patients, whose symptoms generally don't fluctuate.
Correlation does not imply causation. I don't see why IVIG would work. I've tried it myself, with no benefit whatsoever.Personally, I thought immunoadsorption/IVIG helped me get rid of my terrible PEM. We have accounts of massive improvements with this, as well. But in the meantime, we have controlled trials and there's nothing.
On the other hand, LDA would be more consistent with the DecodeME findings, which point towards neurons.
We may have to wait a long time.
ClinicalTrials.gov
The limitations of this study, in my opinion:
The study excludes very severe patients and some severe patients, even though they are among those reporting spectacular improvements with LDA.
The 1 mg dose is relatively high, with no real attempt to identify the minimum effective dose.
Finally, eight weeks of treatment won't be enough to assess a potential loss of effectiveness after several months.
And you're absolutely right about the ridiculous timelines... Late 2028... It's absurd
As I mentioned earlier, this study has its limitations.I'm not 'automatically dismissing'. I'm being skeptical based on unconvincing data from a clinical trial with 50 participants where Abilify didn't reach statistical significance in 9/10 outcome measures.
Isn't it worth trying again? I think the recent discoveries justify new, well-designed trials of a range of drugs acting on neurotransmitters. That would be more worthwhile than studying LDN or curcumin, or even rapamycin or Mestinon.